NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study

NeuroSense Therapeutics announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).